Today's Healthcare Pulse
Allogene Therapeutics CEO David Chang to step down
Allogene Therapeutics announced that chief executive David Chang will leave his role. The news was reported by STAT+ and echoed in a follow‑up piece covering broader pharma updates.
Also developing:
By the numbers: Boston Scientific invests $1.5B for 34% stake in MiRus
Frazier Healthcare-Backed RevSpring Acquires Healthcare Tech Firm TrustCommerce
RevSpring, a revenue‑cycle management platform backed by Frazier Healthcare, announced the acquisition of healthcare‑technology firm TrustCommerce. The deal was sourced from Waud Capital Partners, which acted as the seller. TrustCommerce brings a robust payment‑processing suite that complements RevSpring's existing billing and patient‑engagement tools. The transaction underscores RevSpring's push to offer a fully integrated, end‑to‑end revenue solution for providers.
Prepare Now: Aging Care Will Soon Be Everyone's Reality
As someone researching aging during a time when everyone is trying to extend lifespan (and not necessarily healthspan), I beg you to read this entire🧵. Unless something changes, this is your future reality. You may already be dealing with this if...
Episode 59 - How Clinical Insight Drives Better Pharmacy Outcomes with Employers Health
In this episode, Kevin Wenceslau, Director of Clinical Solutions at Employers Health, explains how their clinical team uses evidence‑based insight to shape pharmacy benefit strategies for employers. He highlights their proactive utilization management—building custom clinical edits, collaborating with PBMs, and...
Value-Based Care Workforce: Bridging the Gap in Clinical Education
The health‑care sector’s shift to value‑based care is outpacing clinicians’ preparation for system‑level responsibilities. While medical training excels at diagnosis and treatment, it often omits the operational, financial, and population‑health skills required for coordinated outcomes. This misalignment creates early‑career attrition...
Silencing Ghrelin The Hunger Hormone
Recent research reveals that several snake lineages have completely lost the hunger hormone ghrelin and its activating enzyme, yet maintain normal energy balance. Modern anti‑obesity drugs, such as GLP‑1 receptor agonists, achieve weight loss by amplifying satiety signals rather than...
Breath and Barking Present a Breakthrough in Cancer Diagnosis
SpotitEarly, led by CEO Shlomi Madar, has unveiled a diagnostic platform that pairs trained detection dogs with electronic sensors and artificial intelligence to analyze patients' breath for early signs of cancer. The system can identify lung, prostate, colorectal and breast...
Mental Health Patients in Wrexham First to Benefit From New Digital Solution
Mental health wards at Wrexham Maelor Hospital have gone live with electronic Prescribing and Medicines Administration (ePMA), the first in Wales to also record discharge medicines in the Shared Medicines Record (SMR). The early‑adopter rollout, led by Betsi Cadwaladr University...
BVI Completes First U.S. Implantations of FDA-Approved FINEVISION HP Trifocal IOL
BVI announced the first successful U.S. implantations of its FDA‑approved FINEVISION HP hydrophobic trifocal intraocular lens. Five leading cataract and refractive surgeons performed the procedures across multiple surgical centers. The lens, cleared by the FDA in October 2025, incorporates BVI’s proprietary POD...
How to Optimize the Revenue Cycle Workforce in 2026
Health systems face margin pressure, rising patient cost responsibility, and payer complexity, prompting a shift in revenue cycle workforce design for 2026. Integrating AI-driven automation with a strategically aligned global workforce and robust governance can improve denial management, clean claim...
EU Pledges €225m to Develop Next Generation of Flu Vaccines
The European Commission has pledged €225 million through a pre‑commercial procurement model to accelerate the development of next‑generation influenza vaccines. Ten entities, including Sanofi and Bavarian Nordic, will receive eight‑year contracts that cover clinical testing through market authorisation. The funding targets...
Statement on the Resignation of the CDC Principal Deputy Director
The Centers for Disease Control and Prevention announced that Dr. Ralph Abraham has resigned as Principal Deputy Director, effective immediately, to address unforeseen family obligations. Abraham, who joined the role in 2024, was recognized for enhancing national preparedness and streamlining...
Why HealthTech Products Fail Clinical Deployment & How To Prevent It
Health‑tech AI pilots are booming, yet MIT’s 2025 State of AI report finds 95% fail to generate value. High‑profile failures like Forward Health’s CarePods and Olive AI illustrate how operational complexity and unfocused expansion derail scaling. The article argues that...
Module 2, Section 1: Target Selection Strategy
The module outlines a five‑dimensional framework for target selection, linking biological relevance, drugability, disease impact, competitive landscape, and development risk. It contrasts first‑in‑class and best‑in‑class strategies, highlighting how pioneering mechanisms can command premium market positions. The content identifies oncology as...
Before AGBT Kicks Off, Ultima Unveils the UG 200
Ultima Genomics announced the UG 200 series, a second‑generation sequencing platform that includes a single‑wafer UG 200 and a dual‑wafer UG 200 Ultra. Both instruments are half the size of the UG 100, cost less (starting at $850,000), and deliver...
A New Era in Neuropsychiatry: Dr. Velichka Valcheva on GH Research’s Rapid-Acting Breakthrough, GH001
GH Research’s inhaled mebufotenin (GH001) demonstrated ultra‑rapid, profound antidepressant effects in a Phase 2b trial for treatment‑resistant depression, with 73% of patients in remission after six months versus ~11% for standard oral therapies. Early‑stage studies in postpartum depression and bipolar disorder...
Gilead Shows Belief in Its Partner’s Cancer Treatment with $7.8 Billion Buyout
Gilead Sciences agreed to acquire the remaining shares of Arcellx for an equity value of $7.8 billion, paying $115 per share—a 79.4% premium to the prior close. The deal secures full rights to Arcellx’s BCMA‑directed CAR‑T therapy anito‑cel, which is in...
Asda Opticians Announces Store Investment and Strengthens Leadership Team
Asda Opticians is committing £2.5 million to upgrade its optical estate, refit 18 stores and modernise diagnostic equipment. The investment also funds a new suite of technical, leadership and personal‑development training, plus a third Level 6 Dispensing Optician apprenticeship cohort beginning September 2026....
Why Healthcare Scheduling Belongs Inside Salesforce
Healthcare scheduling is evolving from a back‑office task into a core operational layer within Salesforce. As providers consolidate patient data, billing, and analytics on the CRM, real‑time coordination of staff, rooms, equipment, and services becomes essential. The article outlines common...
STAT+: Gossamer Lung Disease Drug Fails Late-Stage Study, but Company Will Still Seek FDA Approval
Gossamer Bio announced that its Phase 3 trial of seralutinib for pulmonary arterial hypertension missed its primary endpoint. Patients on seralutinib walked 13 meters farther than placebo over six minutes, but the difference lacked statistical significance. The trial also reported cough...
Trust In CDC Has Now Fallen To 47%, KFF Poll Says. Here Are The Risks
A January 2026 KFF poll shows only 47% of Americans trust the CDC, down from 63% in September 2023. Trust has eroded across the political spectrum, with Democrats at 55%, Republicans at 43%, and independents at 46%. The decline began...
LLMs Still Struggle With Medical Misinformation
A Lancet Digital Health study evaluated 20 large language models with over three million medical prompts, revealing a high susceptibility to misinformation. Neutral prompts led to a 32% acceptance rate of false information, which rose to 46% when embedded in...
The BIG Summit Meets at the Intersection of Patient Advocacy and Venture Investment
At the BIO Investor Growth (BIG) Summit, IBD Ventures’ associate director Nicole Schwerbrock discussed how venture philanthropy and patient advocacy are reshaping investment in inflammatory bowel disease (IBD) research. She explained that patient‑driven funding models complement traditional venture capital by...
Public Health Preparedness: Improved Coordination Needed for HHS’s Emergency Preparedness Programs
The U.S. Department of Health and Human Services (HHS) awarded nearly $900 million in FY 2024 through its Public Health Emergency Preparedness (PHEP) and Hospital Preparedness Program (HPP) to state and local jurisdictions. GAO found that the two HHS agencies managing these...
Bandages Evolve: From Passive Cover to Active Healing
Bandages have been a central component of wound healing for centuries. In the digital health era, the wound healing process will transform the role of bandages from a passive to an active one. We dive into the current and future innovations of...
Rival Drug Wins, Costs Us Marketing Gold
That feeling you get when you run a head-to-head study and the rival drug beats you out. Spending a fortune to hand your competitor a marketing message. Sometimes it feels like $NOVO is snake bit. $LLY https://t.co/gGUjl6iqPg
CMS Renews AHCH’s Deemed Status as Hospice Accreditor
The U.S. Centers for Medicare & Medicaid Services (CMS) has renewed the Accreditation Commission for Health Care’s (ACH C) deemed status as an accreditor for both hospice providers and critical‑access hospitals. The six‑year renewal, effective through 2031, confirms that ACHC’s standards...
Bayesian Designs Decide Faster than Frequentist Group Sequential Methods
Goal-Driven Flexible Bayesian Design presentation updated w/comparison of performance of frequentist group sequential designs: https://t.co/QCZ6DQrm07 . Frequentist approach takes far too long to make a decision by controlling something that is NOT an error prob. #Statistics #rct https://t.co/X2knbmzTuX
Trump's Drug Pricing Deals Promise Lower Consumer Costs
My @CNBC segment on how President Trump's drug pricing deals will achieve many of the initial aims set out by tariff proposals, with respect to reshoring drug manufacturing, and how the biggest consumer impact in terms of lower drug costs...
The State Shows Its Hand
Texas has filed its Required Initial Disclosures in the antitrust lawsuit against Epic Systems, revealing a 12‑category disclosure regime that exceeds the federal FRCP 26 standard. The State’s witness list includes senior Epic executives, technical leaders, recruiting staff, several Epic‑using health...
Doctor-in-the-Loop AI Enh
Evaluating a doctor-in-the-loop AI-agent for multiple myeloma chart reviews [Nov 3, 2025] Karla Mariana Castro Bórquez et al. @HealthTree #ASH25 abs25-15262 PID 4424 https://t.co/MvBeHqOxCg #mmsm #AI #EMR #RWD https://t.co/onY817NfVr
Histopathology Genomics Predicts Myeloma Risk in 1,429 Patients
Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants [Nov 3, 2025] Rajanna et al. @DrOlaLandgren #ASH25 abs25-11635 PID 4008 https://t.co/gOprMCjfgh #mmsm #AI #oncopath https://t.co/pjikEsgfHC
Curing U.S. Health Care: Why a Fair Health Tax Is the Answer
The United States continues to spend more on health care than any other nation while delivering poorer health outcomes, a gap the article attributes to a profit‑driven insurance model. The author argues that incremental reforms have failed and proposes a...
Race‑agnostic AI Accurately Predicts M‑protein in Myeloma
Race agnostic models maintain accuracy in predicting M-protein levels in multiple myeloma [Nov 3, 2025] @rahul2u et al. #ASH25 abs25-11347 PID 2810 https://t.co/A27ozBoW8h #mmsm #AI #CancerDisparities https://t.co/ubJ6NGMFUE
Unstructured Serum Data Hinders AI in Myeloma Care
Unstructured serum electrophoresis data limits real world AI models in multiple myeloma: Evaluation of 384 institutions across United States [Nov 3, 2025] @MalekEhsanMD et al. #ASH25 abs25-11278 PID 2809 https://t.co/mAC8l7xnaG #mmsm #cancerdisparities #hpeonc https://t.co/veJxBV5S0N
Institutional Familiarity & Product-Specific Knowledge Keys for Health Systems Selecting Managed IT Services Partners, KLAS Finds
A February 2026 KLAS Research analysis of 19 health‑system IT outsourcing decisions found pre‑existing vendor relationships to be the top driver of managed‑IT services selection, eclipsing cost, expertise and credibility. The study identified five firms—CereCore, HCTec, Nordic, Impact Advisors and CTG—as...
Patients Favor Step‑Up Dosing for Teclistamab, Talquetamab
Patient perspectives & preferences for step-up dosing and treatment w/ teclistamab & talquetamab: Insights from a patient survey [Nov 3, 2025] @JayHydren et al. @RahulBanerjeeMD abs25-8335 PID 6354 https://t.co/pRlflaSb2I #mmsm #Tcellrx @HealthTree https://t.co/3I9nwsxZMx
Patient‑Centered Registry Accelerates Multiple Myeloma Care
The HealthTree Cure Hub registry: A patient-centered, multicenter approach to advancing multiple myeloma care - Jorge Arturo Hurtado Martínez et al. @HealthTree #ASCO25 Abst e19569 https://t.co/X2pdaIDYth #mmsm
Will AI Eventually De-Skill Doctors? The Evidence Is Trickling In
New research indicates that routine AI assistance can erode physicians' clinical instincts, a phenomenon termed de‑skilling. A 2025 Lancet study found endoscopists' adenoma detection rates dropped from 29% to 22% after regular AI use, suggesting skill decay in non‑AI procedures....
Most Myeloma Patients Prefer Shared Decision‑Making
Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey [Dec 7, 2024] @ManniMD1 et al. - @HealthTree https://t.co/jATJRKEfB2 #ASH24 Abst 2281 #mmsm HT @Taxkourel
Side Effect Severity Shapes Patient Autonomy in Myeloma Care
Patient-Centered Care in Hematology: How Side Effect Severity Influences Decision-Making Autonomy in Relapsed Refractory Multiple Myeloma [Dec 8, 2024] Martinez et al. #ASH24 Abst 706 https://t.co/l7SHPBwbna #mmsm HT @Taxkourel
OMG as a Marker of Resiliency to Neurodegenerative Processes
Researchers identified oligodendrocyte myelin glycoprotein (OMG) in blood as a marker inversely associated with cortical amyloid‑β deposition and neurodegeneration. Large‑scale plasma proteomics across more than a dozen cohorts showed lower OMG levels in individuals with Alzheimer’s disease, other dementias, and...
Strong Care Team Ties Shape Myeloma Treatment Choices
The effect of care team-patient relationship on decision-making in relapsed/refractory multiple myeloma - @MyelomaTeacher et al. @HealthTree #ASCO24 Abstract e19530 https://t.co/Ss5LZHH0Oj #mmsm
Patients Reveal Hopeful Views on Myeloma Cure
A survey on the patient perspective on cure in multiple myeloma [Oct 9, 2022] @ManniMD1 et al. @HealthtreeMM @TheLancetHaem https://t.co/1XhKT7AWGi #mmsm
How FDA's Action Against Non-FDA-Approved GLP-1 Products Affects the Competitive Landscape
Jay Bregman, CEO of Andel, says the FDA’s pending crackdown on non‑FDA‑approved GLP‑1 compounds is long overdue and will target the burgeoning market of compounded semaglutide. He estimates roughly 1.5 million patients currently rely on these unapproved products, a figure he...
Patient‑Driven Platform Accelerates Multiple Myeloma Research
.@HealthtreeMM Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles & Accelerate Research in Multiple Myeloma [3/10/22] @NSweeneyPhd @AhlstromJenny @FaithEDavies1 @mtmdphd @JCOCCI_ASCO https://t.co/WOwLb9Eozv @myelomacrowd #mmsm https://t.co/dZzhU3N32Q
Patient Portal Streamlines Myeloma Imaging and Pathology Reporting
. @HealthtreeMM Patient Portal mediated myeloma patient reported diagnostic imaging and pathology testing - @NSweeneyPhd @AhlstromJenny @mtmdphd J Clin Oncol 38: 2020 (suppl; abstr e20565) #ASCO20 https://t.co/CRLXETpeMm #mmsm #oncorad #oncopath https://t.co/m1UGDimLWm
Low‑dose Dexamethasone Improves Survival in Newly Diagnosed Myeloma
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm https://t.co/FjBnt6yIox
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/QdWETmSoiR
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor‑Dex for Myeloma‑Induced Kidney Damage
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/paGRlHV1Dv
Critical Thinking Must Outpace AI in Healthcare
Jan Herzhoff, president of global health businesses at Elsevier, emphasized the importance of critical thinking over sole reliance on AI to prevent de-skilling in healthcare at the India AI Impact Summit 2026. https://t.co/hexOguFdCt #AI #Elsevier #health #India